Moreover, we observed that ALT discriminated the group of MASLD + fibrosis from MASLD, which means that this enzyme increased as MASLD progressed, and liver damage advanced. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.